Isavuconazonium Sulfate Injection and Naloxegol
Determining the interaction of Isavuconazonium Sulfate Injection and Naloxegol and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Isavuconazonium can significantly increase the blood levels of naloxegol. You may be more likely to experience side effects and withdrawal symptoms such as sweating, tearing, runny nose, chills, diarrhea, abdominal pain, anxiety, insomnia, irritability, restlessness, and yawning. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of naloxegol, which is primarily metabolized by the isoenzyme. When a single 25 mg dose of naloxegol was administered during multiple dosing of 240 mg once daily extended-release diltiazem, a moderate CYP450 3A4 inhibitor, naloxegol peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 2.9- and 3.4-fold, respectively. Increased exposure to naloxegol may precipitate opioid withdrawal symptoms such as hyperhidrosis, lacrimation, rhinorrhea, chills, diarrhea, abdominal pain, anxiety, insomnia, irritability, restlessness, and yawning.
MANAGEMENT: Concomitant use of naloxegol with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the dosage of naloxegol should be reduced to 12.5 mg once daily and the patient closely monitored for opioid withdrawal symptoms.
- "Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: isavuconazonium
Brand name: Cresemba
Synonyms: Isavuconazonium, Isavuconazonium Sulfate
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Isavuconazonium Sulfate Injection-Naloxegol Oxalate
- Isavuconazonium Sulfate Injection-Naloxone
- Isavuconazonium Sulfate Injection-Naloxone and pentazocine
- Isavuconazonium Sulfate Injection-Naloxone Auto-Injection
- Isavuconazonium Sulfate Injection-Naloxone Hydrochloride
- Isavuconazonium Sulfate Injection-Naloxone Injection
- Naloxegol-Isentress
- Naloxegol-Isentress (Raltegravir Chewable Tablets)
- Naloxegol-Isentress (Raltegravir Powder for Oral Suspension)
- Naloxegol-Isentress (Raltegravir Tablets)
- Naloxegol-Isentress HD
- Naloxegol-Isibloom